Deviaterikova Alena A, Kasatkin Vladimir V, Velichovsky Boris B
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.
Russian Academy of Education, Moscow, Russia.
Psychol Russ. 2021 Mar 31;14(1):39-48. doi: 10.11621/pir.2021.0104. eCollection 2021.
Fatigue is the most common complaint by children both during and after cancer treatment, but in Russia, there is no reliable method for assessing fatigue.
To develop a Russian version of the Turkish Scale for the Assessment of Fatigue in Pediatric Oncology Patients Ages 7-18.
Our first step was to translate all the items of the Turkish questionnaire into Russian. Then, through discussion, we created a single proposition for each item. The next step was obtaining expert opinions to assess the validity. Once the expert estimates agreed, a pilot version of the questionnaire was formed. The next step was to collect a large sample of patients to study the reliability and validity of the questionnaire.
As a result of factor analysis, three factors were identified. The first factor was "fatigue associated with actions;" the second was "fatigue as feeling;" and the third was "fatigue associated with sleep difficulties." The children's and parents' versions had the same factor structure.
This study showed the possibility of using the questionnaire in a Russian sample. That's why it is necessary to continue collecting and analyzing data in this direction. The reliability of the test was also assessed. The reliability of the parent version scored a Cronbach's alpha of 0.91. The reliability of the children's version showed a Cronbach's alpha of 0.93.
疲劳是儿童在癌症治疗期间及之后最常见的主诉，但在俄罗斯，尚无可靠的疲劳评估方法。
开发适用于7至18岁儿科肿瘤患者的土耳其疲劳评估量表的俄语版本。
我们的第一步是将土耳其问卷的所有项目翻译成俄语。然后，通过讨论，我们为每个项目创建了一个单一命题。下一步是征求专家意见以评估效度。一旦专家评估达成一致，就形成了问卷的试用版。下一步是收集大量患者样本以研究问卷的信度和效度。
通过因子分析，确定了三个因子。第一个因子是“与行动相关的疲劳”；第二个是“作为感觉的疲劳”；第三个是“与睡眠困难相关的疲劳”。儿童版和家长版具有相同的因子结构。
本研究表明该问卷在俄罗斯样本中使用的可能性。因此有必要继续朝这个方向收集和分析数据。还评估了测试的信度。家长版的信度Cronbach's alpha得分为0.91。儿童版的信度Cronbach's alpha为0.93。
